Search results
We are a global e-Health SaaS company who create technology to optimise how patients and their physicians detect wheeze. Our products include wheezo®, the respiri TM mobile app and Respiri health portal. An Australian based company, our operations span multiple geographic locations.
Respiri Limited (ASX:RSH, OTCQB:RSHUF) is an Australian e-Health SaaS company supporting respiratory health management focusing primarily on supporting the US healthcare market. Respiri is listed on the Australian Securities Exchange (ASX) and trades on the OTCQB under the ticker “RSHUF” for North American based investors
Respiri can integrate wheezo® medical device and wheeze detection into remote patient monitoring programs to claim CPT codes.
Respiri Limited is uniquely positioned to revolutionise chronic disease management globally and is focused on the US market, where our suite of evidence-based programs qualify for Current Procedural Terminology (CPT) Code reimbursement.
As a differentiated RPM provider, Respiri’s mission is to improve health outcomes for patients with chronic diseases from cardiovascular, diabetes, obesity and, exclusively, respiratory disease.
Oct 31, 2019 · The latest Respiri Limited [RSH] news, articles, data and analysis from The Australian Financial Review.
Nov 8, 2022 · Australian digital health company Respiri has started to roll out its digital remote patient monitoring (RPM) system for asthma and chronic obstructive pulmonary disease (COPD) in the US, with...
